Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 9 METERS BIOPHARMA, INC.NMTR · Entity 114271 | Director | March 29, 2023 | March 31, 2023 |
| BIOMERICA INCBMRA · Entity 8171 | Director | December 09, 2021 | December 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
9 METERS BIOPHARMA, INC.
Report date March 29, 2023 · Filed March 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,907 |
Reported balance
After 2023-03-29 transaction · row 1
1 source rowRow 1 · 2023-03-29 · Grant · Acquired 7,885 · Balance 85,907 F1: Represents Restricted Stock Units ("RSUs") granted pursuant to the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting date. The RSUs vest as follows: 3,943 shares vest on April 15, 2023 and 3,942 shares vest on December 31, 2023. The vesting of the December 31, 2023 RSUs will accelerate upon a Change in Control prior to December 31, 2023. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 1,075 |
Reported balance
Holding disclosure · report date 2023-03-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,075 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") granted pursuant to the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting date. The RSUs vest as follows: 3,943 shares vest on April 15, 2023 and 3,942 shares vest on December 31, 2023. The vesting of the December 31, 2023 RSUs will accelerate upon a Change in Control prior to December 31, 2023.
BIOMERICA INC
Report date December 09, 2021 · Filed December 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2031-12-09 | Direct | 170,000 |
Reported balance
After 2021-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-09 · Grant · Acquired 25,000 · Balance 170,000 F1: Not applicable |
| Common stockSEC Table I · non-derivative | Direct | 8,700 |
Reported balance
Holding disclosure · report date 2021-12-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 8,700 |
Filing footnotes · ownership attribution and instrument terms
F1: Not applicable
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date March 22, 2022 · Filed March 22, 2022
Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 1
1 source rowRow 1 · 2022-03-22 · Other · Disposed 1,166,866 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-22 · Disposition to issuer · Disposed 11,685 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-22 · Disposition to issuer · Disposed 48,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-22 · Disposition to issuer · Disposed 48,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-22 · Disposition to issuer · Disposed 85,760 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2018 Filed Dec 21, 2018 23:37 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon Qualified Stock Option · Derivative | 35,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001513162-18-000324 · primary_doc.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 35,000 shares Expires 2028-12-20 F1 · price: Not applicable Read SEC document |
| May 23, 2018 Filed May 25, 2018 18:22 UTC | BIOMERICA INC BMRA · Entity 8171 | OtherCommon Stock | 6,700 | $3.73 | $24,991.00 |
DisclosureSEC source: 0001513162-18-000142 · primary_doc.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 F1 · kind: Purchased through an S-3 registration statement filed 06/30/2017, file #333-219130. (Prospectus filed 12/04/2017) Read SEC document |
| April 10, 2018 Filed Apr 13, 2018 19:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 100,000 | $2.06 | $206,000.00 |
DisclosureSEC source: 0000899243-18-010157 · doc4.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,499,542 F4 · security: The shares of Common Stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F5 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in these footnotes. F3 · price: On April 10, 2018, the Reporting Person sold an aggregate of 100,000 shares of the Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.13 per share and the lowest sale price was $2.00 per share. Read SEC document |
| April 06, 2018 Filed Apr 13, 2018 19:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 13,576 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010157 · doc4.xml · derivative · entry 5 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,576 shares Expires 2018-04-06 F2 · kind: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018. F2 · derivative.exercise_date: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018. Read SEC document |
| April 06, 2018 Filed Apr 13, 2018 19:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 285,305 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010157 · doc4.xml · derivative · entry 4 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,305 shares Expires 2018-04-06 F1 · kind: Pursuant to the Reporting Person's retirement agreement previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on August 29, 2017 (the "Retirement Agreement"), the future vesting of these Restricted Stock Units ("RSUs") terminated and in lieu the Reporting Person received a one-time issuance of the Issuer's common stock ("Common Stock"). Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018. F1 · derivative.exercise_date: Pursuant to the Reporting Person's retirement agreement previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on August 29, 2017 (the "Retirement Agreement"), the future vesting of these Restricted Stock Units ("RSUs") terminated and in lieu the Reporting Person received a one-time issuance of the Issuer's common stock ("Common Stock"). Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018. Read SEC document |
| April 06, 2018 Filed Apr 13, 2018 19:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 13,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010157 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,599,542 F2 · price: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018. Read SEC document |
| April 06, 2018 Filed Apr 13, 2018 19:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 285,305 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010157 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,585,966 F1 · price: Pursuant to the Reporting Person's retirement agreement previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on August 29, 2017 (the "Retirement Agreement"), the future vesting of these Restricted Stock Units ("RSUs") terminated and in lieu the Reporting Person received a one-time issuance of the Issuer's common stock ("Common Stock"). Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018. Read SEC document |
| January 22, 2018 Filed Jan 25, 2018 02:05 UTC Amendment | BIOMERICA INC BMRA · Entity 8171 | GrantNon qualified stock option · Derivative | 25,000 | Not disclosed Strike: $3.90 | Not disclosed |
DisclosureSEC source: 0001513162-18-000031 · primary_doc.xml · derivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-22 F2 · price: Inapplicable. F1 · derivative.exercise_date: Exercisable 01/22/2019. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:31 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon qualified stock option · Derivative | 25,000 | Not disclosed Strike: $3.90 | Not disclosed |
DisclosureSEC source: 0001513162-18-000024 · primary_doc.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 25,000 shares Expires 2018-01-22 F2 · price: Inapplicable. F1 · derivative.exercise_date: Exercisable 01/22/2019. Read SEC document |
| January 19, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 84,800 | $2.60 | $220,480.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 10 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300,661 F11 · security: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F12 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F10 · kind: On January 19, 2018, the Reporting Person sold an aggregate of 84,800 shares of the Issuer's Common Stock at a weighted average price of $2.60 per share. The highest sale price for the Common Stock was $2.67 per share and the lowest sale price was $2.50 per share. F11 · price: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. Read SEC document |
| January 18, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 266,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · derivative · entry 15 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 266,667 shares Expires 2018-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 266,667 RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on January 18, 2018. Read SEC document |
| January 18, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 75,200 | $2.58 | $194,016.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 9 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385,461 F11 · security: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F12 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F9 · kind: On January 18, 2018, the Reporting Person sold an aggregate of 75,200 shares of the Issuer's Common Stock at a weighted average price of $2.58 per share. The highest sale price for the Common Stock was $2.60 per share and the lowest sale price was $2.50 per share. F10 · price: On January 19, 2018, the Reporting Person sold an aggregate of 84,800 shares of the Issuer's Common Stock at a weighted average price of $2.60 per share. The highest sale price for the Common Stock was $2.67 per share and the lowest sale price was $2.50 per share. Read SEC document |
| January 18, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 266,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 8 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,460,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 266,667 RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on January 18, 2018. F9 · price: On January 18, 2018, the Reporting Person sold an aggregate of 75,200 shares of the Issuer's Common Stock at a weighted average price of $2.58 per share. The highest sale price for the Common Stock was $2.60 per share and the lowest sale price was $2.50 per share. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 91,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · derivative · entry 14 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,667 shares Expires 2018-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 91,667 RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, these RSUs vested on January 17, 2018. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 96,837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · derivative · entry 13 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,837 shares Expires 2018-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 96,837 RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on January 17, 2018. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 108,000 | $2.57 | $277,560.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 7 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,193,994 F11 · security: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F12 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F7 · kind: On January 17, 2018, the Reporting Person sold an aggregate of 108,000 shares of the Issuer's Common Stock at a weighted average price of $2.57 per share. The highest sale price for the Common Stock was $2.65 per share and the lowest sale price was $2.50 per share. F8 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 266,667 RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on January 18, 2018. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 91,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 6 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,301,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 91,667 RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, these RSUs vested on January 17, 2018. F7 · price: On January 17, 2018, the Reporting Person sold an aggregate of 108,000 shares of the Issuer's Common Stock at a weighted average price of $2.57 per share. The highest sale price for the Common Stock was $2.65 per share and the lowest sale price was $2.50 per share. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 96,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 5 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,210,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 96,837 RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on January 17, 2018. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 91,667 RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, these RSUs vested on January 17, 2018. Read SEC document |
| January 04, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 278,993 | $2.85 | $795,130.05 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 4 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,113,490 F11 · security: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F12 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F4 · kind: On January 4, 2018, the Reporting Person sold an aggregate of 278,993 shares of the Issuer's Common Stock at a weighted average price of $2.85 per share. The highest sale price for the Common Stock was $2.90 per share and the lowest sale price was $2.80 per share. F5 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 96,837 RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on January 17, 2018. Read SEC document |
| January 03, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 162,509 | $2.78 | $451,775.02 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,392,483 F11 · security: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F12 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · kind: On January 3, 2018, the Reporting Person sold an aggregate of 162,509 shares of the Issuer's Common Stock at a weighted average price of $2.78 per share. The highest sale price for the Common Stock was $2.85 per share and the lowest sale price was $2.70 per share. F4 · price: On January 4, 2018, the Reporting Person sold an aggregate of 278,993 shares of the Issuer's Common Stock at a weighted average price of $2.85 per share. The highest sale price for the Common Stock was $2.90 per share and the lowest sale price was $2.80 per share. Read SEC document |
| January 02, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 795,730 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · derivative · entry 12 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 795,730 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the Retirement Agreement. These RSUs were related to previously granted time-based vesting RSUs issued to the Reporting Person pursuant to the Plan that were unvested as of the retirement date, which in lieu thereof, the Reporting Person received a one-time issuance common stock shares under the Plan, the number of which was determined by dividing (A) the net present value of such RSUs by (B) the 30-day VWAP as of the retirement date. Read SEC document |
| January 02, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 250,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · derivative · entry 11 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the Reporting Person's retirement agreement previously filed with a Current Report on Form 8-K on August 29, 2017 (the "Retirement Agreement"). These Restricted Stock Units ("RSUs") were related to future performance milestones which terminated and in lieu the Reporting Person received a one-time issuance of common stock shares under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Read SEC document |
| January 02, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 795,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,554,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the Retirement Agreement. These RSUs were related to previously granted time-based vesting RSUs issued to the Reporting Person pursuant to the Plan that were unvested as of the retirement date, which in lieu thereof, the Reporting Person received a one-time issuance common stock shares under the Plan, the number of which was determined by dividing (A) the net present value of such RSUs by (B) the 30-day VWAP as of the retirement date. F3 · price: On January 3, 2018, the Reporting Person sold an aggregate of 162,509 shares of the Issuer's Common Stock at a weighted average price of $2.78 per share. The highest sale price for the Common Stock was $2.85 per share and the lowest sale price was $2.70 per share. Read SEC document |
| January 02, 2018 Filed Jan 19, 2018 19:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001565 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,759,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the Reporting Person's retirement agreement previously filed with a Current Report on Form 8-K on August 29, 2017 (the "Retirement Agreement"). These Restricted Stock Units ("RSUs") were related to future performance milestones which terminated and in lieu the Reporting Person received a one-time issuance of common stock shares under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). F2 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the Retirement Agreement. These RSUs were related to previously granted time-based vesting RSUs issued to the Reporting Person pursuant to the Plan that were unvested as of the retirement date, which in lieu thereof, the Reporting Person received a one-time issuance common stock shares under the Plan, the number of which was determined by dividing (A) the net present value of such RSUs by (B) the 30-day VWAP as of the retirement date. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 619 | $2.75 | $1,702.25 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 11 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,262 Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionOptions · Derivative | 34,265 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · derivative · entry 16 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,265 shares Expires 2020-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: The options exercised were acquired from September 20, 2017 to September 21, 2017. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionOptions · Derivative | 25,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · derivative · entry 15 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 65,405 | $2.75 | $179,863.75 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 10 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,881 F5 · price: On September 20, 2017, the Reporting Person sold an aggregate of 65,405 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.78 per share and the lowest sale price was $2.75 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 34,265 | $2.43 | $83,263.95 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 9 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: The options exercised were acquired from September 20, 2017 to September 21, 2017. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 25,000 | $2.26 | $56,500.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 8 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionOptions · Derivative | 13,661 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · derivative · entry 14 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,902 shares Expires 2018-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The options exercised were acquired from September 19, 2017 to September 20, 2017. Read SEC document |
| September 19, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 24,516 | $2.75 | $67,419.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 7 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,516,022 Read SEC document |
| September 19, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 13,661 | $2.01 | $27,458.61 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 6 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The options exercised were acquired from September 19, 2017 to September 20, 2017. Read SEC document |
| September 18, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 6,000 | $2.85 | $17,100.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 5 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,526,876 Read SEC document |
| September 15, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionOptions · Derivative | 33,026 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · derivative · entry 13 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,026 shares Expires 2022-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The options exercised were acquired from September 15, 2017 to September 19, 2017. Read SEC document |
| September 15, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionOptions · Derivative | 45,421 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · derivative · entry 12 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,421 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 54,833 | $2.90 | $159,015.70 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 4 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,532,876 Read SEC document |
| September 15, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 33,026 | $1.96 | $64,730.96 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,587,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The options exercised were acquired from September 15, 2017 to September 19, 2017. Read SEC document |
| September 15, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 45,421 | $1.78 | $80,849.38 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2017 Filed Sep 22, 2017 17:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 50,000 | $2.95 | $147,500.00 |
DisclosureSEC source: 0000899243-17-022447 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,262 F1 · price: On September 14, 2017, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.95 per share. The highest sale price for the Common Stock was $2.98 per share and the lowest sale price was $2.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 15,100 | $1.99 | $30,049.00 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · nonDerivative · entry 6 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,559,262 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F7 · price: On March 31, 2017, the Reporting Person sold an aggregate of 15,100 shares of the Issuer's Common Stock at a weighted average price of $1.99 per share. The highest sale price for the Common Stock was $2.03 per share and the lowest sale price was $1.93 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 30, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 12,500 | $1.86 | $23,250.00 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · nonDerivative · entry 5 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,574,362 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F6 · price: On March 30, 2017, the Reporting Person sold an aggregate of 12,500 shares of the Issuer's Common Stock at a weighted average price of $1.86 per share. The highest sale price for the Common Stock was $1.88 per share and the lowest sale price was $1.86 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 28, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 49,500 | $1.90 | $94,050.00 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · nonDerivative · entry 4 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586,862 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F5 · price: On March 28, 2017, the Reporting Person sold an aggregate of 49,500 shares of the Issuer's Common Stock at a weighted average price of $1.90 per share. The highest sale price for the Common Stock was $1.93 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 32,000 | $1.88 | $60,160.00 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,636,362 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F4 · price: On March 27, 2017, the Reporting Person sold an aggregate of 32,000 shares of the Issuer's Common Stock at a weighted average price of $1.88 per share. The highest sale price for the Common Stock was $1.90 per share and the lowest sale price was $1.88 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 1,795 | $1.90 | $3,410.50 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668,362 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. Read SEC document |
| March 15, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 524,418 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · derivative · entry 7 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,170 Underlying: Common Stock · 524,418 shares Expires 2017-03-15 F1 · date: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") as follows: (i) 15,888 shares of common stock were granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017; (ii) 140,000 shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 15, 2017; (iii) 96,837 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13 F2 · date: (Continued from footnote 1) ; (iv) 266,667 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (a) September 14, 2017 and (b) February 23, 2018; and (v) 5,026 shares of common stock reported on this Form 4 became exercisable on March 21, 2017 and were acquired by the Reporting Person on March 22, 2017 in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") as follows: (i) 15,888 shares of common stock were granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017; (ii) 140,000 shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 15, 2017; (iii) 96,837 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13 F2 · kind: (Continued from footnote 1) ; (iv) 266,667 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (a) September 14, 2017 and (b) February 23, 2018; and (v) 5,026 shares of common stock reported on this Form 4 became exercisable on March 21, 2017 and were acquired by the Reporting Person on March 22, 2017 in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| March 15, 2017 Filed Mar 31, 2017 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 524,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-009070 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director · President, CEO & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,670,157 F1 · date: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") as follows: (i) 15,888 shares of common stock were granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017; (ii) 140,000 shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 15, 2017; (iii) 96,837 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13 F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") as follows: (i) 15,888 shares of common stock were granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017; (ii) 140,000 shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 15, 2017; (iii) 96,837 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13 F2 · kind: (Continued from footnote 1) ; (iv) 266,667 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (a) September 14, 2017 and (b) February 23, 2018; and (v) 5,026 shares of common stock reported on this Form 4 became exercisable on March 21, 2017 and were acquired by the Reporting Person on March 22, 2017 in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") as follows: (i) 15,888 shares of common stock were granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017; (ii) 140,000 shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 15, 2017; (iii) 96,837 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13 F2 · price: (Continued from footnote 1) ; (iv) 266,667 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (a) September 14, 2017 and (b) February 23, 2018; and (v) 5,026 shares of common stock reported on this Form 4 became exercisable on March 21, 2017 and were acquired by the Reporting Person on March 22, 2017 in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 18:03 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 375,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003153 · doc4.xml · derivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2020-03-18 F1 · kind: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.